Ballesteros-Tato A
Immunotherapy. 2014; 6(11):1207-20.
PMID: 25496335
PMC: 4289615.
DOI: 10.2217/imt.14.83.
Lee C, Pang P, Yeung W, Tissot B, Panico M, Lao T
J Biol Chem. 2009; 284(22):15084-96.
PMID: 19240032
PMC: 2685690.
DOI: 10.1074/jbc.M807960200.
Song Y, Lee Y, Narasimhan P, Chan P
J Cereb Blood Flow Metab. 2006; 27(4):764-75.
PMID: 16868554
PMC: 1831759.
DOI: 10.1038/sj.jcbfm.9600379.
Maas R, Dullens H, Den Otter W
Cancer Immunol Immunother. 1993; 36(3):141-8.
PMID: 8439974
PMC: 11038683.
DOI: 10.1007/BF01741084.
Dubinett S, Patrone L, Tobias J, Cochran A, Wen D, McBride W
Cancer Immunol Immunother. 1993; 36(3):156-62.
PMID: 8382559
PMC: 11038993.
DOI: 10.1007/BF01741086.
Studies on IL-2 production and T-cell colony forming unit in patients with chronic renal failure.
Ha S, Cho H, Lee H, Kim H, Choi K, Han D
Korean J Intern Med. 1993; 8(2):86-92.
PMID: 8031728
PMC: 4532092.
DOI: 10.3904/kjim.1993.8.2.86.
In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors.
Huland E, Falk B, Hubner D, Huland H
J Cancer Res Clin Oncol. 1995; 121(5):285-90.
PMID: 7768966
DOI: 10.1007/BF01209595.
Tolerance of thymic cytotoxic T lymphocytes to allogeneic H-2 determinants encountered prethymically: evidence for expression of anti-H-2 receptors prior to entry into the thymus.
Morrissey P, Kruisbeek A, Sharrow S, Singer A
Proc Natl Acad Sci U S A. 1982; 79(6):2003-7.
PMID: 6979047
PMC: 346110.
DOI: 10.1073/pnas.79.6.2003.
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
Cheever M, Greenberg P, Fefer A, Gillis S
J Exp Med. 1982; 155(4):968-80.
PMID: 6977616
PMC: 2186656.
DOI: 10.1084/jem.155.4.968.
Interleukin-2 allows in vivo induction of anti-erythrocyte autoantibody production in nude mice associated with the injection of rat erythrocytes.
Reimann J, DIAMANTSTEIN T
Clin Exp Immunol. 1981; 43(3):641-4.
PMID: 6974628
PMC: 1537175.
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.
Greenberg P, Cheever M, Fefer A
J Exp Med. 1981; 154(3):952-63.
PMID: 6974221
PMC: 2186470.
DOI: 10.1084/jem.154.3.952.
H-2 restriction as a consequence of intentional priming. Frequency analysis of alloantigen-restricted, trinitrophenyl-specific cytotoxic T lymphocyte precursors within thymocytes of normal mice.
Stockinger H, Bartlett R, Pfizenmaier K, Rollinghoff M, Wagner H
J Exp Med. 1981; 153(6):1629-39.
PMID: 6973002
PMC: 2186190.
DOI: 10.1084/jem.153.6.1629.
Alloreactive and H-2-restricted Lyt 23 cytotoxic T lymphocytes derive from a common pool of antecedent Lyt 123 precursors.
Hardt C, Pfizenmaier K, Rollinghoff M, Klein J, Wagner H
J Exp Med. 1980; 152(5):1413-8.
PMID: 6968813
PMC: 2186006.
DOI: 10.1084/jem.152.5.1413.
T-cell growth factor (interleukin 2) and terminal transferase activity in human leukemias and lymphoblastic cell lines.
Mertelsmann R, Gillis S, Steinmann G, Ralph P, Stiehm M, Koziner B
Blut. 1981; 43(2):99-103.
PMID: 6942897
DOI: 10.1007/BF00320468.
Major histocompatibility complex antigen expression on the epithelium of the developing thymus in normal and nude mice.
Jenkinson E, van Ewijk W, Owen J
J Exp Med. 1981; 153(2):280-92.
PMID: 6940949
PMC: 2186090.
DOI: 10.1084/jem.153.2.280.
Chemical carcinogens transform BHK cells by inducing a recessive mutation.
BOUCK N, DI MAYORCA G
Mol Cell Biol. 1982; 2(2):97-105.
PMID: 6810094
PMC: 369762.
DOI: 10.1128/mcb.2.2.97-105.1982.
Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo.
Hardt C, Rollinghoff M, Pfizenmaier K, Mosmann H, Wagner H
J Exp Med. 1981; 154(2):262-74.
PMID: 6790656
PMC: 2186429.
DOI: 10.1084/jem.154.2.262.
Interleukin 2 is mitogenic for nu/nu and nu/+ murine spleen cells.
Lipsick J, Kaplan N
Proc Natl Acad Sci U S A. 1981; 78(4):2398-402.
PMID: 6787601
PMC: 319353.
DOI: 10.1073/pnas.78.4.2398.
T-Cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation.
Gillis S, Mizel S
Proc Natl Acad Sci U S A. 1981; 78(2):1133-7.
PMID: 6785748
PMC: 319961.
DOI: 10.1073/pnas.78.2.1133.
Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes.
Efrat S, KAEMPFER R
Proc Natl Acad Sci U S A. 1984; 81(9):2601-5.
PMID: 6609365
PMC: 345117.
DOI: 10.1073/pnas.81.9.2601.
